Spirogen spinoff ADC will put the proceeds into advancing its cancer-fighting antibody drug conjugates, having raised more than $530m from backers including AstraZeneca.

Switzerland-based cancer therapy developer ADC Therapeutics has filed for a $150m initial public offering on the New York Stock Exchange that would enable pharmaceutical company AstraZeneca to exit. Spun off from AstraZeneca subsidiary Spirogen in 2011, ADC is developing antibody drug conjugates that will target haematological malignancies and solid tumours. The IPO proceeds will support…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.